@article{c00c5ac03a924bcabff138e522bb48fb,
title = "Screening and eradication of Helicobacter pylori for gastric cancer prevention: The Taipei global consensus",
abstract = "Objective A global consensus meeting was held to review current evidence and knowledge gaps and propose collaborative studies on population-wide screening and eradication of Helicobacter pylori for prevention of gastric cancer (GC). Methods 28 experts from 11 countries reviewed the evidence and modified the statements using the Delphi method, with consensus level predefined as ≥80% of agreement on each statement. The Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach was followed. Results Consensus was reached in 26 statements. At an individual level, eradication of H. pylori reduces the risk of GC in asymptomatic subjects and is recommended unless there are competing considerations. In cohorts of vulnerable subjects (eg, first-degree relatives of patients with GC), a screen-and-treat strategy is also beneficial. H. pylori eradication in patients with early GC after curative endoscopic resection reduces the risk of metachronous cancer and calls for a re-examination on the hypothesis of a € the point of no return'. At the general population level, the strategy of screen-and-treat for H. pylori infection is most cost-effective in young adults in regions with a high incidence of GC and is recommended preferably before the development of atrophic gastritis and intestinal metaplasia. However, such a strategy may still be effective in people aged over 50, and may be integrated or included into national healthcare priorities, such as colorectal cancer screening programmes, to optimise the resources. Reliable locally effective regimens based on the principles of antibiotic stewardship are recommended. Subjects at higher risk of GC, such as those with advanced gastric atrophy or intestinal metaplasia, should receive surveillance endoscopy after eradication of H. pylori. Conclusion Evidence supports the proposal that eradication therapy should be offered to all individuals infected with H. pylori. Vulnerable subjects should be tested, and treated if the test is positive. Mass screening and eradication of H. pylori should be considered in populations at higher risk of GC.",
author = "Liou, {Jyh Ming} and Peter Malfertheiner and Lee, {Yi Chia} and Sheu, {Bor Shyang} and Kentaro Sugano and Cheng, {Hsiu Chi} and Yeoh, {Khay Guan} and Hsu, {Ping I.} and Goh, {Khean Lee} and Varocha Mahachai and Takuji Gotoda and Chang, {Wei Lun} and Chen, {Mei Jyh} and Chiang, {Tsung Hsien} and Chen, {Chieh Chang} and Wu, {Chun Ying} and Leow, {Alex Hwong Ruey} and Wu, {Jeng Yih} and Wu, {Deng Chyang} and Hong, {Tzu Chan} and Hong Lu and Yoshio Yamaoka and Francis Megraud and Chan, {Francis K.L.} and Sung, {Joseph J.Y.} and Lin, {Jaw Town} and Graham, {David Y.} and Wu, {Ming Shiang} and El-Omar, {Emad M.}",
note = "Funding Information: The consensus meeting was funded by GEST with support from industries, National Taiwan University Hospital, and Ministry of Science and Technology of Taiwan. The funding sources had no role in the planning and organisation of the meeting, study design, data collection, analysis or interpretation, report writing or the decision to submit this manuscript for publication. All authors had full access to the data and participated in the decision to submit for publication. Funding Information: Funding The study was funded by the National Taiwan University Hospital (grant number: NTUH 107-P05; 109-P03), the Ministry of Science and Technology, Executive Yuan, ROC, Taiwan (grant number: TCTC 108-2321-B-002 -040 - and MOST 108-2314-B-002 -187, 108-2314-B-002 -209 -), the Ministry of Health and Welfare of Taiwan (grant number: MOHW107-TDU-B-211-123002, MOHW108-CDC-C-114-112102), the “Center of Precision Medicine” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (grant number: NTU-107L9014-1), the Liver Disease Prevention & Treatment Research Foundation, Taiwan, and the Gastroenterological Society of Taiwan (GEST). The GEST received funding from the Takeda Taiwan Co. Ltd (APTC-01), the Eisai Co. Ltd, the Swiss Pharmaceutical Co. (APTC-02), Ltd, the Panion & BF Biotech Inc. (APTC-03), and the Harvester Trading Co. LTD (APTC-04). for the 10th Asian Pacific Topic Conference. DYG is supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant DK56338 which funds the Texas Medical Center Digestive Diseases Center. EME-O is funded by grants from the Australian Federal Government to the St George and Sutherland Medical Research Foundation. The funding source had no role in study design, data collection, analysis or interpretation, report writing or the decision to submit this paper for publication.",
year = "2020",
month = dec,
day = "1",
doi = "10.1136/gutjnl-2020-322368",
language = "English",
volume = "69",
pages = "2093--2112",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "12",
}